Clover’s RSV Vaccine Candidate SCB-1019 Gains U.S. IND Clearance for Revaccination Study
Clover Biopharmaceuticals, Ltd. has received FDA clearance for its Investigational New Drug (IND) application and has initiated a Phase I revaccination clinical trial for SCB-1019, its non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine. The trial, now enrolling participants, aims to assess the safety, reactogenicity, and immunogenicity of SCB-1019, which is based on Clover’s proprietary Trimer-Tag vaccine technology platform.
The study includes up to 160 older adults (ages 60-85) who were previously vaccinated with GSK’s RSV vaccine (AREXVY) at ...
